Skip to main content
OpenTrials
Completed

NCT Number: NCT05229081

Impact of Pharmacist-led Educational Intervention on Pneumococcal Vaccination Rates in Cancer Patients

According to the World Health Organization (WHO), immunization; is defined as making a person immune or resistant to an infectious disease by applying a vaccine (1). The primary indicator of an effective immunization is that adequate vaccination rates have been achieved. The risk of cancer and chronic diseases increases with advancing age, which increases the importance of immunization in adults.

Cancer patients, one of the patient groups for whom adult immunization is a priority and crucial, are subjected to immunosuppressive medications, making them vulnerable to infections. In cancer patients, infections are severe, antimicrobial treatments are sometimes insufficient, leading to morbidity and mortality. One of these infections is pneumococcal disease caused by Streptococcus pneumonia, with high morbidity and mortality in cancer patients. Invasive pneumococcal disease is seen 23-48 times more frequently in cancer patients compared to healthy individuals. In many countries worldwide, the 13-valent pneumococcal conjugate vaccine and the 23-valent polysaccharide pneumococcal vaccine, both developed to prevent pneumonia caused by Streptococcus pneumonia, are successfully used in childhood vaccination programs within the framework of WHO's immunization policies. However, in Turkey, like in the rest of the world, the required adult immunization rates have not been achieved yet. Immunization rates among cancer patients, one of the patient groups for whom adult vaccination is required, remain below the targeted levels. Pharmacists, one of the health professionals, have significant contributions to increasing vaccination rates in adults. According to studies, pharmacists can help raise immunization rates by providing education and information. In Turkey, no study has been conducted to assess the impact of vaccination education on cancer patients' attitudes and actions about the pneumococcal vaccine. This study aimed to determine the impact of pharmacist-led pneumonia and pneumococcal vaccine education on cancer patients' vaccination attitudes, knowledge, and vaccination rates.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pneumonia, Bacterial Bacterial Infections Bacterial Infections and Mycoses Cancer Gram-Positive Bacterial Infections Infections Lung Diseases Neoplasms Pneumococcal Infections Pneumonia Respiratory Tract Diseases Respiratory Tract Infections Streptococcal Infections

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hacettepe University Faculty of Medicine Department of Medical Oncology

Ankara, 06100, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The study will involve patients who have all of the following features simultaneously.

  • patients who visit medical oncology outpatient clinics,
  • patients who are over 18 years old,
  • patients who have been diagnosed with cancer for less than two years,
  • patients who are in remission stage (as determined by a medical oncologist),
  • patients who have never had the pneumococcal vaccine.

Exclusion criteria

  • patients who could not communicate in Turkish,
  • patients who were illiterate,
  • patients who had visual/auditory/cognitive impairments,
  • patients who had previously received a pneumococcal vaccine recommendation,
  • patients who did not know their pneumococcal immunization status
  • patients who want to leave the study

Treatment and study plan

vaccine education

Behavioral

The educational content was developed based on research and expert perspectives and included general information about immunization, pneumonia, and pneumococcal vaccines, as well as vaccine myths. This information was first conveyed to the patients verbally, and then booklets with the same material were handed to them. The Pneumococcal Conjugate Vaccine 13 (PCV13) vaccination was recommended based on Infectious Disease Society of America (IDSA), Advisory Committee on Immunization Practices (ACIP), and national adult immunization guidelines.

Primary outcomes

  1. Vaccination attitude

    Time frame: 3 months after education provision

    changes in the patients' Vaccination Attitudes Examination (VAX )Scale scores (This scale consists of 12 items and four subgroups (mistrust of vaccine benefit, worries about unforeseen future effects, concerns about commercial profiteering, and preference for natural immunity) to be responded on a 6-point Likert scale, and the total score ranges between 12-72. The higher scores indicate the anti-vaccination attitudes of the patients.)

  2. Knowledge about pneumonia and the pneumococcal vaccine

    Time frame: 3 months after education provision

    changes in the patients' Vaccination Knowledge Questionnaire (VKQ) (that consists of 13 questions to be answered as 'yes/no/unknown')

  3. Vaccination behavior

    Time frame: 3 months after education provision

    changes in the patients' vaccination rates (The vaccination status of patients with the pneumococcal vaccine will be asked.)

Secondary outcomes

  1. the relationship between demographic characteristics and pneumococcal vaccination behavior

    Time frame: 3 months after education provision

    determining factors affecting pneumococcal vaccination behavior in patients. Parameters (age, gender, educational status, etc.) that differ statistically between vaccinated and unvaccinated patients will be determined, and then logistic regression will be made for these parameters to determine the factors affecting vaccinating behavior.

Sponsors and collaborators

Lead sponsor

Hacettepe University

Other

Registry information

Official study title

Impact of Pharmacist-led Educational Intervention on Pneumococcal Vaccination Rates in Cancer Patients: A Randomized Controlled Study

Important dates

Study start
2019
Primary completion
2020
Study completion
2021
First posted
Feb 8, 2022
Registry last updated
Feb 8, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.